An Open-Label, Multi-Center, Study to Investigate Drug-Drug Interactions Between AT2220 (Duvoglustat Hydrochloride) and Alglucosidase Alfa in Patients With Pompe Disease

Trial Profile

An Open-Label, Multi-Center, Study to Investigate Drug-Drug Interactions Between AT2220 (Duvoglustat Hydrochloride) and Alglucosidase Alfa in Patients With Pompe Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 19 May 2014

At a glance

  • Drugs Duvoglustat (Primary) ; Alglucosidase alfa
  • Indications Glycogen storage disease type II
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Amicus Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top